+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Autoinjectors Market (3rd Edition), 2020-2030

  • ID: 4988848
  • Report
  • January 2020
  • Region: Global
  • 602 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • Biomerics
  • Europlaz Technologies
  • Lineage Therapeutics
  • Paramit
  • SHL Group
  • MORE

Overview

More than 40% of the US population is estimated to be suffering from some form of a chronic health condition. According to the US National Health Council, over 75% of the nation’s healthcare expenditure is on the treatment of chronic diseases, such as diabetes. The major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repeated visits to hospitals / out-patient clinics. Over time, a variety of solutions enabling self-administration of injectable drugs have been developed and introduced into the market.

In a relatively short time period, the self-injection devices market has grown into a prominent and promising segment within the pharmaceutical industry. Autoinjectors represent one such type of device that has witnessed increased adoption among patients, especially for the treatment of emergency situations, such as anaphylactic shocks. According to developers, such devices are relatively easier to use, compared to other parenteral drug delivery systems, and have integrated needle-safety features. In fact, autoinjectors have been proven to have resolved a number of injection-related tolerability issues faced by patients.

Over the years, several players have launched proprietary autoinjectors-based combination products for use across a variety of therapeutic areas. EpiPen® is one of the most popular and widely recognized autoinjectors (based on historical sales data) available in the market today. Examples of other autoinjector combination products approved in 2019 include, NUCALA Autoinjector (GlaxoSmithKline), Vyleesi™ Autoinjector (AMAG Pharmaceuticals® / Palatin Technologies), Fasenra® (AstraZeneca) and Teribone™ (Asahi Kasei Pharma). Autoinjectors are also considered to be a potential pharmaceutical life cycle management tool; they are used by many pharmaceutical players to expand marketing exclusivity periods of proprietary drugs.

For example, lyophilized Enbrel® was reformulated for delivery via the SureClick® autoinjector; this granted the drug almost 11 additional years of patent protection. It is also worth highlighting that there are a number of efforts underway to improve the existing generation of autoinjectors. Incorporation of healthcare data acquisition and analysis features, addition of smart functions to deal with medication-related errors, and improved safety measures, are some of the upgrades that device developers claim to be in the process of developing. In this context, it is worth mentioning that, so far, over 4,600 patent applications have been filed for autoinjectors and affiliated products / technologies. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope Of the Report

The ‘Global Autoinjectors Market (3rd Edition), 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current market landscape of companies engaged in developing and / or manufacturing autoinjectors, providing information on the usability (disposable and reusable), type of primary drug container (cartridge, syringe and vial), volume of container, type of dose (fixed and variable), route of administration (intradermal, intramuscular and subcutaneous), actuation mechanism (automatic and manual) and feedback mechanism integrated in the device. It also provides details on the developers, highlighting their year of establishment, company size (small-sized, mid-sized and large), location of headquarters and location of manufacturing facilities
  • Information on companies that are developing drugs in combination with autoinjectors, featuring details on initial year of approval (for marketed products), phase of development, usability of the device, route of administration (intracavernous, intramuscular and subcutaneous), type of drug molecule (antibody, peptide, protein and small molecule), dose strength, therapeutic area and other approved dosage forms (for marketed products). In addition, the section provides details on the company, including year of establishment, company size and location of headquarters
  • A competitiveness analysis of various disposable and reusable autoinjectors, taking into consideration supplier power (based on year of establishment and company size) and key product specifications, such as route of administration, primary drug container used, injector actuation mechanism, type of dose and user friendliness of the product.
  • An in-depth analysis of the various patents that have been filed/granted related to autoinjectors, till August 2019, highlighting details on key parameters, such as type of patent, publication year, issuing authority, CPC classification, emerging focus areas and leading industry players (on the basis of number of patents). It also includes a detailed patent benchmarking and an insightful valuation analysis.
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength and diversity of product portfolio, route of administration, actuation mechanism, geographical presence / reach and supplier power of each company.
  • A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future, shortlisted on the basis of an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • A list of key opinion leaders (KOLs) within this domain who were short-listed based on their contributions (such as involvement in clinical trials and being mentioned in patent applications); it features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain.
  • Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records; the study provides a list of all the drugs that are currently being delivered via autoinjectors.
  • A case study on the role of CMOs offering services for drug delivery devices; it features a list of service providers, highlighting the various types of services offered for different types of drug-delivery devices.  
  • A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.
  • Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for autoinjector devices. Based on parameters, such as number of commercialized combination products, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] usability (disposable and reusable), [B] route of administration (subcutaneous and intramuscular), [C] type of molecule (monoclonal antibody, peptide, protein and small molecule) [D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications), and [E] key geographies (North America, Europe, Asia-Pacific and rest of the World).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

  • David Daily (CEO and Co-founder, DALI Medical Devices)
  • Douglas Marenzi (Managing Director, PHC Injection Technologies)
  • Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical)
  • Anonymous (Co-Founder, US-based Mid-Sized Company)
  • Anonymous (Senior Program Officer, US-based Organization)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Biomerics
  • Europlaz Technologies
  • Lineage Therapeutics
  • Paramit
  • SHL Group
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional Parenteral Delivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Prevention
3.4.2.1. Government Legislation for the Prevention of Needlestick Injuries
3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment in Emergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements
3.6. Types of Self- Administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors
3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging of Autoinjectors
3.7.4. Benefits of Autoinjectors
3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products
3.9. Future Perspectives

4. PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary Drug Containers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge
4.3.2.1.3. Cartridges Available in the Market
4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle
4.3.2.2.3. Prefilled Syringe Systems Available in the Market
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes
4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market
4.4. Comparison of Fabrication Materials

5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: List of Devices
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.2.3. Analysis by Volume of Container
5.2.4. Analysis by Type of Dose
5.2.5. Analysis by Route of Administration
5.2.6. Analysis by Actuation Mechanism
5.2.7. Analysis by Type of Feedback Mechanism
5.3. Autoinjectors: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Geographical Location of Headquarters
5.3.4. Analysis by Geographical Location of Manufacturing Facilities

6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis
6.4.1. Disposable Autoinjectors
6.4.2. Reusable Autoinjectors

7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
7.1. Scope and Methodology
7.2. Brand Positioning Matrix: Antares Pharma
7.3. Brand Positioning Matrix: BD
7.4. Brand Positioning Matrix: Elcam Drug Delivery Devices
7.5. Brand Positioning Matrix: Oval Medical Technologies
7.6. Brand Positioning Matrix: SHL Medical
7.7. Brand Positioning Matrix: Ypsomed
7.8. Brand Positioning Matrix: DALI Medical Devices

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Issuing Authority
8.3.3. Analysis by CPC Symbols
8.4. Emerging Focus Areas
8.5. Leading Players: Analysis by Number of Patents
8.6. Autoinjectors: Patent Benchmarking Analysis
8.6.1. Analysis by Patent Characteristics
8.6.2. Analysis by Geography
8.7. Autoinjectors: Patent Valuation Analysis

9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products: List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Type of Molecule
9.2.5. Analysis by Dose Strength
9.2.6. Analysis by Therapeutic Area
9.2.7. Analysis by Other Approved Dosage Forms
9.3. Autoinjector Combination Products: List of Pipeline Drugs
9.3.1. Analysis by Phase of Development
9.3.2. Analysis by Route of Administration
9.3.3. Analysis by Type of Molecule
9.3.4. Analysis by Therapeutic Area
9.4. Autoinjector Combination Products: List of Developers
9.4.1. Analysis by Year of Establishment
9.4.2. Analysis by Company Size
9.4.3. Analysis by Location of Headquarters

10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Autoinjector-based Combination Products Available / Under Evaluation
10.3. Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Available Treatment Options: Adrenaline
10.3.2.1. Mechanism of Action
10.3.2.2. History of Development
10.3.3.3. Marketed Autoinjectors
10.3.3.3.1. Adrenaclick®
10.3.3.3.2. Allerject / Auvi-Q® (Formerly called e-cue™)
10.3.3.3.3. Anapen®
10.3.3.3.4. Emerade®
10.3.3.3.5. EpiPen® / EpiPen® Jr
10.3.3.3.6. Jext®
10.3.3.3.7. EpiPen® / EpiPen Jr®
10.3.3.4. Pipeline Autoinjectors
10.3.3.4.1. EpiQ
10.3.3.4.2. ANDIPen
10.3.3.4.3. MiniEpi
10.3.3.4.4. Zeneo® Adrenaline
10.3.3.5. Other Dosage Forms
10.3.3.6. Historical Sales of Approved Products
10.4. Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Available Treatment Options: Interferon β-1a and Interferon β-1b
10.4.2.1. Mechanism of Action
10.4.2.2. History of Development
10.4.2.3. Interferon β-1a Autoinjectors
10.4.2.3.1. Avonex® Pen
10.4.2.3.2. PLEGRIDY® Pen
10.4.2.3.3. Rebif® Rebidose®
10.4.2.3.4. RebiSmart™
10.4.2.3.5. Rebiject II®
10.4.2.3.6. ReciGen® Physioject™
10.4.2.4. Interferon β-1b Autoinjectors
10.4.2.4.1. BETACONNECT™
10.4.2.4.2. BETAJECT® Comfort / Betacomfort®
10.4.2.4.3. Betaject® Lite
10.4.2.4.4. ExtaviJect® 30G / ExtaviPro® 30G
10.4.2.5. Other Marketed Autoinjectors
10.4.2.5.1. Cinnomer®40 Physioject™
10.4.2.5.2. CSYNC™ Autoinjector
10.4.2.5.3. WhisperJECT™
10.4.2.5.4. Remurel® Autoxon
10.4.2.6. Other Dosage Forms
10.4.2.7. Historical Sales of Approved Products
10.4.2.7.1. Interferon β-1a
10.4.2.7.2. Interferon β-1b
10.5. Migraine
10.5.1. Overview and Epidemiology
10.5.2. Available Treatment Options: Sumatriptan Succinate
10.5.2.1 History of Development
10.5.2.2 Marketed Autoinjectors
10.5.2.2.1. ALSUMA®
10.5.2.2.2. IMITREX STATdose Pen®
10.5.2.2.3. Zembrace SymTouch
10.5.2.2.4. Aimovig SureClick® Autoinjector
10.5.2.2.5. Emgality® Prefilled Pen
10.5.5. Other Dosage Forms
10.5.6. Historical Sales of Approved Products
10.6. Rheumatoid Arthritis
10.6.1. Overview and Epidemiology
10.6.2. Available Treatment Options
10.6.2.1 History of Development
10.6.2.2. Marketed Autoinjectors for Rheumatoid Arthritis
10.6.2.2.1. Actemra®
10.6.2.2.2. CIMZIA® AutoClicks® Prefilled Pen
10.6.2.2.3. Enbrel SureClick®
10.6.2.2.4. Hulio Prefilled Pen
10.6.2.2.5. HUMIRA® Pen
10.6.2.2.6. ORENCIA® ClickJect™
10.6.2.2.7. OTREXUP™
10.6.2.2.8. Rasuvo® Autoinjector
10.6.2.2.9. SIMPONI® SmartJect® Autoinjector
10.6.2.2.10. KEVZARA® Prefilled Pen
10.6.2.2.11. IMRALDI™ Prefilled Pen
10.6.4. Historical Sales of Approved Products

11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
11.1. Chapter Overview
11.2. Marketed Drug Candidates for Delivery via Autoinjectors
11.2.1. Most Likely Drug Candidates
11.2.2. Likely Drug Candidates
11.2.3. Less Likely Drug Candidates
11.2.4. Unlikely Drug Candidates
11.3. Clinical Drug Candidates for Delivery via Autoinjectors
11.3.1. Most Likely Drug Candidates
11.3.2. Likely Drug Candidates
11.3.3. Less Likely Drug Candidates
11.3.4. Unlikely Drug Candidates

12. KEY PLAYERS
12.1. Chapter Overview
12.2. Antares Pharma
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.3.1. Autoinjectors: Product Details
12.2.3.1.1. Vibex®
12.2.3.1.2. QuickShot™
12.2.3.1.3. BigShot™
12.2.4. Key Collaborators
12.2.4.1. Teva Pharmaceutical
12.2.4.2. Ferring Pharmaceuticals
12.2.4.3. AMAG Pharmaceuticals
12.2.4.4. JCR Pharmaceuticals
12.2.4.5. Pfizer
12.2.4.6. Idorsia Pharmaceuticals
12.2.5. Recent Developments and Future Outlook
12.3 Consort Medical (Previously Bespak)
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Technology Overview
12.3.4. Product Portfolio
12.3.4.1. Autoinjectors: Product Details
12.3.4.1.1. Syrina®
12.3.4.1.2. OTS™ Autoinjector
12.3.4.1.3. Viscala Autoinjector
12.3.5. Key Collaborators
12.3.5.1. Aesica Pharmaceuticals
12.3.5.2. Undisclosed Global Biopharmaceutical Company
12.3.5.3. Regeneron Pharmaceuticals
12.3.6. Recent Developments and Future Outlook
12.4. DALI Medical Devices
12.4.1. Company Overview
12.4.2. Product Portfolio
12.4.2.1. Autoinjectors: Product Details
12.4.2.1.1. SAN-L™
12.4.2.1.2. SAN-P
12.4.2.1.3. SAN-DV
12.4.2.1.4. SAN-DV Pro
12.4.3. Collaborations
12.4.3.1. Elcam Medical
12.4.4. Recent Developments and Future Outlook
12.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
12.5.1. Company Overview
12.5.2. Product Portfolio
12.5.2.1. Autoinjectors: Product Details
12.5.2.1.1. Flexi-Q Disposable Autoinjectors
12.5.2.1.1.1. Flexi-Q PFS
12.5.2.1.1.2. Flexi-Q HV
12.5.2.1.1.3. Flexi -Q DV
12.5.2.1.2. Flexi-Q Reusable Autoinjectors
12.5.2.1.2.1. Flexi-Q mMU
12.5.2.1.2.2. Flexi-Q eMU-C / P
12.5.2.1.2.3. Flexi-Q EAI
12.5.3. Comparison of Elcam Medical Autoinjectors
12.5.4. Key Collaborators
12.5.4.1. DALI Medical Devices
12.5.5. Recent Developments and Future Outlook
12.6. Jiangsu Delfu Medical Devices
12.6.1. Company Overview
12.6.2. Financial Information
12.6.3. Product Portfolio
12.6.3.1. Autoinjectors: Overview and Specifications
12.6.3.1.1. Components of Delfu Autoinjectors
12.6.3.1.2. Applications of Delfu Autoinjectors
12.6.3.1.3. Features of Delfu Autoinjectors
12.6.3.1.4. Advantages of Delfu Autoinjectors
12.6.3.1.5. Specifications of Delfu Autoinjectors
12.6.3.2. Autoinjectors: Product Details
12.6.3.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector
12.6.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
12.6.3.2.3. DZ-IA Auto Injector Pen
12.6.3.2.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens
12.6.3.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen
12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen
12.6.4. Recent Developments and Future Outlook
12.7. Oval Medical Technologies
12.7.1. Company Overview
12.7.2. Product Portfolio
12.7.2.1. Autoinjectors: Product Details
12.7.2.1.1 ArQ®
12.7.2.1.2 ArQ® - Bios
12.7.2.1.3 ArQ® - Tempo
12.7.2.1.4 ArQ® - Vita
12.7.3. Key Collaborators
12.7.3.1. SOLIZE
12.7.4. Recent Developments and Future Outlook
12.8. Owen Mumford
12.8.1. Company Overview
12.8.2. Product Portfolio
12.8.2.1. Autoinjectors: Product Details
12.8.2.1.1. Autoject® Micro
12.8.2.1.2. Autoject® 2
12.8.2.1.3. Autoject® Mini
12.8.2.1.4. Autoject® Visco
12.8.2.1.5. UniSafe® Autoinjector
12.8.2.1.6. UniSafe® Connected Auto-injector
12.8.3. Key Collaborators
12.8.3.1. Sanofi Aventis
12.8.4. Recent Developments and Future Outlook
12.9. SHL Group
12.9.1. Company Overview
12.9.2. Product Portfolio
12.9.2.1. Two-Step Disposable Autoinjectors: Product Details
12.9.2.1.1 Amber® (Pushclick™ Technology)
12.9.2.1.2. Molly®
12.9.2.1.3. Molly®RNS
12.9.2.1.4. Molly® 2.25
12.9.2.1.5. Rotaject®
12.9.2.1.6. Bertha®
12.9.2.1.7. DAI® 2
12.9.2.1.8. Maggie®
12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors
12.9.2.2. Three-Step Disposable Autoinjectors: Product Details
12.9.2.2.1. DAI®
12.9.2.2.2. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
12.9.2.2.3. VSDI®+NIT®
12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors
12.9.2.2.5. PPI® Injector (Rotaject™ Pressure Release Technology)
12.9.3. Key Collaborators
12.9.3.1. Schreiner MediPharm
12.9.3.2. QuiO
12.9.4. Recent Developments and Future Outlook
12.10. Union Medico®
12.10.1. Company Overview
12.10.2. Technology Overview
12.10.3. Product Portfolio
12.10.3.1. Autoinjectors: Product Details
12.10.3.1.1 45˚ Autoinjector
12.10.3.1.2 45˚/ S Autoinjector
12.10.3.1.3 45˚/ M Autoinjector
12.10.3.1.4 45˚/ R Autoinjector
12.10.3.1.5 Comparison of 45˚ Autoinjectors
12.10.3.1.6 90˚Autoinjector
12.10.3.1.7 90˚/ S Autoinjector
12.10.3.1.8 90˚/ M Autoinjector
12.10.3.1.9 90˚/ XL Autoinjector
12.10.3.1.10 SuperGrip™ Autoinjector
12.10.3.1.11 Exclusive™ Autoinjector
12.10.3.1.12 Comparison of 90˚ Autoinjectors
12.10.4. Recent Developments and Future Outlook
12.11. Ypsomed
12.11.1. Company Overview
12.11.2. Financial Information
12.11.3. Product Portfolio
12.11.3.1. Autoinjectors: Product details
12.11.3.1.1. YpsoMate® ,YpsoMate® 2.25 and YpsoMate® 2.25Pro
12.11.3.1.2. VarioJect™
12.11.3.1.3. Comparison of Autoinjectors
12.11.4. Key Collaborators
12.11.4.1. I-SENS
12.11.4.2. Royal Philips
12.11.4.3. JDRF
12.11.5. Recent Developments and Future Outlook

13. EMERGING PLAYERS
13.1. Chapter Overview
13.2. AktiVax
13.3. Amneal Pharmaceuticals
13.4. kaléo
13.5. MiniEpi
13.6. Nemera
13.7. Nuance Designs
13.8. Windgap Medical
13.9. Xeris Pharmaceuticals
13.10. Zion Clinical Pharmacy

14. KOL ANALYSIS
14.1. Chapter Overview
14.2. Methodology
14.3. KOL Analysis: Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
14.3.1. Geographical Distribution of KOLs
14.3. KOL Analysis: Patent Assignees
14.3.1. Geographical Distribution of KOLs

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
16.1. Chapter Overview
16.2. Challenges Associated with Medical Device Manufacturing
16.3. Role of CMOs in Medical Device Manufacturing
16.4. Services Offered by Medical Device CMOs
16.5. Advantages Offered by Medical Device CMOs
16.6. Risks Associated with Outsourcing to CMOs
16.7. Drug Delivery Service Providers
16.8. Concluding Remarks

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Global Autoinjectors Market, 2020-2030 (By Value)
17.3.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Value)
17.3.2. Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Value)
17.3.4. Autoinjectors Market in North America, 2020-2030 (By Value)
17.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Value)
17.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.3.5. Autoinjectors Market in Europe, 2020-2030 (By Value)
17.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Value)
17.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.3.6. Autoinjectors Market in Asia Pacific, 2020-2030 (By Value)
17.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.3.7. Autoinjectors Market in Rest of the World, 2020-2030 (By Value)
17.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.4. Global Autoinjectors Market, 2020-2030 (By Volume)
17.4.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Volume)
17.4.2. Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Volume)
17.4.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.4.4. Autoinjectors Market in North America, 2020-2030 (By Volume)
17.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Volume)
17.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.3.5. Autoinjectors Market in Europe, 2020-2030 (By Volume)
17.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.3.6. Autoinjectors Market in Asia Pacific, 2020-2030 (By Volume)
17.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.3.7. Autoinjectors Market in Rest of the World, 2020-2030 (By Volume)
17.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.5. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Value)
17.5.1. Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Value)
17.5.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Value)
17.5.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.5.2. Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Value)
17.5.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Value)
17.5.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.5.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Value)
17.5.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.5.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.5.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Value)
17.5.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.5.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.6. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Volume)
17.6.1. Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Volume)
17.6.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Volume)
17.6.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.6.2. Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Volume)
17.6.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.6.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.6.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Volume)
17.6.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.6.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.6.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Volume)
17.6.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.6.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.7. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Value)
17.7.1. Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Value)
17.7.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Value)
17.7.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.7.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Value)
17.7.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Value)
17.7.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.7.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Value)
17.7.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.7.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.7.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Value)
17.7.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.7.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.8. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Volume)
17.8.1. Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Volume)
17.8.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Volume)
17.8.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.8.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Volume)
17.8.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.8.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.8.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Volume)
17.8.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.8.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.8.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Volume)
17.8.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.8.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.9. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Value)
17.9.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Value)
17.9.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Value)
17.9.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.9.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Value)
17.9.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Value)
17.9.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.9.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Value)
17.9.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.9.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.9.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Value)
17.9.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.9.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.10. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Volume)
17.10.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Volume)
17.10.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Volume)
17.10.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.10.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Volume)
17.10.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.10.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.10.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Volume)
17.10.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.10.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.10.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Volume)
17.10.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.10.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.11. Global Autoinjectors Market for Migraine, 2020-2030 (By Value)
17.11.1. Autoinjectors Market for Migraine in North America, 2020-2030 (By Value)
17.11.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Value)
17.11.1.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.1.3. Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.11.2. Autoinjectors Market for Migraine in Europe, 2020-2030 (By Value)
17.11.2.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Value)
17.11.2.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.2.3. Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.11.3. Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Value)
17.11.3.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.11.3.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.3.3. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.11.4. Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Value)
17.11.4.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.11.4.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.4.3. Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.12. Global Autoinjectors Market for Migraine, 2020-2030 (By Volume)
17.12.1. Autoinjectors Market for Migraine in North America, 2020-2030 (By Volume)
17.12.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Volume)
17.12.1.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.1.3. Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.12.2. Autoinjectors Market for Migraine in Europe, 2020-2030 (By Volume)
17.12.2.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.12.2.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.2.3. Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.12.3. Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Volume)
17.12.3.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.12.3.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.3.3. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.12.4. Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Volume)
17.12.4.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.12.4.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.4.3. Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.13. Global Autoinjectors Market for Diabetes, 2020-2030 (By Value)
17.13.1. Autoinjectors Market for Diabetes in North America, 2020-2030 (By Value)
17.13.1.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Value)
17.13.1.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.1.3. Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.13.2. Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Value)
17.13.2.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Value)
17.13.2.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.2.3. Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.13.3. Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Value)
17.13.3.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.13.3.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.3.3. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.13.4. Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Value)
17.13.4.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.13.4.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.4.3. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.14. Global Autoinjectors Market for Diabetes, 2020-2030 (By Volume)
17.14.1. Autoinjectors Market for Diabetes in North America, 2020-2030 (By Volume)
17.14.1.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Volume)
17.14.1.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.1.3. Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.14.2. Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Volume)
17.14.2.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.14.2.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.2.3. Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.14.3. Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Volume)
17.14.3.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.14.3.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.3.3. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.14.4. Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Volume)
17.14.4.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.14.4.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.4.3. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.15. Global Autoinjectors Market for Other Indications, 2020-2030 (By Value)
17.15.2. Autoinjectors Market for Other Indications in North America, 2020-2030 (By Value)
17.15.2.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Value)
17.15.2.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.2.3. Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Value)
17.15.3. Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Value)
17.15.3.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Value)
17.15.3.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.3.3. Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)
17.15.4. Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Value)
17.15.4.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.15.4.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.4.3. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)
17.15.5. Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Value)
17.15.5.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.15.5.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.5.3. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)
17.16. Global Autoinjectors Market for Other Indications, 2020-2030 (By Volume)
17.16.1. Autoinjectors Market for Other Indications in North America, 2020-2030 (By Volume)
17.16.1.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Volume)
17.16.1.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.1.3. Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.16.2. Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Volume)
17.16.2.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.16.2.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.2.3. Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.16.3. Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Volume)
17.16.3.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.16.3.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.3.3. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)
17.16.4. Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Volume)
17.16.4.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.16.4.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.4.3. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

18. CONCLUSION
18.1. Chapter Overview
18.2. Key Takeaways

19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. DALI Medical Devices
19.2.1. Company Snapshot
19.2.2. Interview Transcript: David Daily, CEO and Co-Founder
19.3. PHC
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Douglas Marenzi, Managing Director
19.4. Elcam Medical
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Components of an Autoinjector
Figure 3.4 Cartridge Based Autoinjectors versus Prefilled Syringe Based Autoinjectors
Figure 3.5 Classification of Autoinjectors
Figure 5.1 Autoinjectors: Distribution by Usability
Figure 5.2 Autoinjectors: Distribution by Type of Primary Container
Figure 5.3 Autoinjectors: Distribution by Volume of Container
Figure 5.4 Autoinjectors: Distribution by Type of Dose
Figure 5.5 Autoinjectors: Distribution by Route of Administration
Figure 5.6 Autoinjectors: Distribution by Actuation Mechanism
Figure 5.7 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 5.8 Autoinjector Device Developers: Distribution by Year of Establishment
Figure 5.9 Autoinjector Device Developers: Distribution by Company Size
Figure 5.10 Autoinjector Device Developers: Distribution by Geographical Location of Headquarters
Figure 5.11 Autoinjector Device Developers: Distribution by Geographical Location of Manufacturing Facilities
Figure 6.1 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 6.2 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 7.1 Brand Positioning Matrix: Antares Pharma
Figure 7.2 Brand Positioning Matrix: BD
Figure 7.3 Brand Positioning Matrix: Elcam Drug Delivery Devices
Figure 7.4 Brand Positioning Matrix: Oval Medical Technologies
Figure 7.5 Brand Positioning Matrix: SHL Medical
Figure 7.6 Brand Positioning Matrix: Ypsomed
Figure 7.7 Brand Positioning Matrix: DALI Medical Devices
Figure 8.1 Patent Portfolio: Distribution by Type of Patent
Figure 8.2 Patent Portfolio: Cumulative Distribution by Publication Year
Figure 8.3 Patent Portfolio: Year-wise Distribution by Publication Year
Figure 8.4 Patent Portfolio: Distribution by Issuing Authority
Figure 8.5 Patent Portfolio: Distribution by CPC Symbols
Figure 8.6 Patent Portfolio: Emerging Focus Areas
Figure 8.7 Leading Players: Distribution by Number of Patents
Figure 8.8 Patent Portfolio: Benchmarking by Patent Characteristics
Figure 8.9 Patent Portfolio: Benchmarking International Patents
Figure 8.10 Patent Portfolio: Distribution of Patents by Geography and Type
Figure 8.11 Patent Portfolio: Distribution by Patent Age
Figure 8.12 Patent Portfolio: Valuation Analysis
Figure 9.1 Approved Autoinjector Combination Products: Distribution by Initial Year of Approval
Figure 9.2 Approved Autoinjector Combination Products: Distribution by Usability
Figure 9.3 Approved Autoinjector Combination Products: Distribution by Route of Administration
Figure 9.4 Approved Autoinjector Combination Products: Distribution by Type of Molecule
Figure 9.5 Approved Autoinjector Combination Products: Distribution by Dose Strength
Figure 9.6 Approved Autoinjector Combination Products: Distribution by Therapeutic Area
Figure 9.7 Approved Autoinjector Combination Products: Distribution by Other Approved Dosage Forms
Figure 9.8 Pipeline Autoinjector Combination Products: Distribution by Phase of Development
Figure 9.9 Pipeline Autoinjector Combination Products: Distribution by Route of Administration
Figure 9.10 Pipeline Autoinjector Combination Products: Distribution by Type of Molecule
Figure 9.11 Pipeline Autoinjector Combination Products: Distribution by Therapeutic Area
Figure 9.12 Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 9.13 Autoinjector Combination Product Developers: Distribution by Company Size
Figure 9.14 Autoinjector Combination Product Developers: Distribution by Geographical Location of Headquarters
Figure 10.1 Anaphylaxis: History of Drug Development
Figure 10.2 EpiPen®: Historical Drug Sales (USD Billion), 2012-2017
Figure 10.3 Multiple Sclerosis: History of Drug Development
Figure 10.4 Interferon β-1a: Historical Sales (USD Billion), 2014-H1 2019
Figure 10.5 Interferon β-1b: Historical Sales (USD Million), 2014-H1 2019
Figure 10.6 Migraine: History of Drug Development
Figure 10.7 Migraine: Historical Drug Sales (USD Million), 2014-H1 2019
Figure 10.8 Rheumatoid Arthritis: History of Drug Development
Figure 10.9 Rheumatoid Arthritis: Historical Drug Sales (USD Billion), 2014-H1 2019
Figure 11.1 Likely Drug Candidates: Marketed Drugs
Figure 11.2 Likely Drug Candidates: Pipeline Drugs
Figure 12.1 Antares Pharma: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 12.2 Antares Pharma: Product Portfolio
Figure 12.3 Consort Medical: Annual Revenues, FY 13/14-FY 18/19 (GBP Million)
Figure 12.4 Consort Medical Injectables: Syrina Autoinjectors
Figure 12.5 DALI Medical Devices: Autoinjectors
Figure 12.6 SAN-L: Mechanism of Drug Delivery
Figure 12.7 SAN-P: Mechanism of Drug Delivery
Figure 12.8 SAN-DV: Mechanism of Drug Delivery
Figure 12.9 SAN-DV Pro: Mechanism of Drug Delivery
Figure 12.10 Elcam Medical: Product Portfolio
Figure 12.11 Elcam Medical: Flexi-Q Autoinjectors
Figure 12.12 Flexi-Q PFS: Components
Figure 12.13 Flexi-Q PFS: Mechanism of Drug Delivery
Figure 12.14 Flexi-Q DV: Components
Figure 12.15 Flexi-Q DV: Mechanism of Drug Delivery
Figure 12.16 Flexi-Q mMU: Components
Figure 12.17 Flexi-Q eMU: Components
Figure 12.18 Flexi-Q mMU / Flexi-Q eMU: Mechanism of Drug Delivery
Figure 12.19 Flexi-Q EAI: Mechanism of Drug Delivery
Figure 12.20 Delfu Autoinjectors: Components
Figure 12.21 Applications of Delfu Autoinjectors
Figure 12.22 Oval Medical Technologies: Product Portfolio
Figure 12.23 ArQ®: Mechanism of Drug Delivery
Figure 12.24 ArQ®-Bios: Mechanism of Drug Delivery
Figure 12.25 ArQ®-Tempo: Mechanism of Drug Delivery
Figure 12.26 Owen Mumford: Product Portfolio
Figure 12.27 Autoject® Micro: Mechanism of Drug Delivery
Figure 12.28 Autoject® 2 Autoinjector: Mechanism of Drug Delivery
Figure 12.29 Autoject® Mini: Mechanism of Drug Delivery
Figure 12.30 SHL Medical: Product Portfolio
Figure 12.31 SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 12.32 SHL Medical: Cartridge Based Autoinjectors
Figure 12.33 SHL Medical: Two-Step Autoinjectors
Figure 12.34 SHL Medical Two-Step Autoinjectors: Mechanism of Drug Delivery
Figure 12.35 SHL Medical: Three-Step Autoinjectors
Figure 12.36 DAI®: Mechanism of Drug Delivery
Figure 12.37 SDI-MIX®+NIT™: Mechanism of Drug Delivery
Figure 12.38 Union Medico: 45˚Autoinjector Portfolio
Figure 12.39 Union Medico: Parts of 45˚/R Autoinjector
Figure 12.40 Union Medico: Types of 45˚/R Autoinjector
Figure 12.41 Union Medico: Types of 90˚ Autoinjectors
Figure 12.42 Exclusive™: Components
Figure 12.43 Ypsomed: Annual Revenues, FY 14/15-FY 18/19 (CHF Million)
Figure 12.44 Ypsomed: Sales by Business Divisions, FY 18/19 (CHF Million, %)
Figure 12.45 Ypsomed: Product Portfolio
Figure 12.46 YpsoMate®: Mechanism of Drug Delivery
Figure 12.47 VarioJect™: Mechanism of Drug Delivery
Figure 14.1 Geographical Distribution of Principal Investigators
Figure 14.2 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 14.3 Geographical Distribution of Patent Applicants
Figure 15.1 Autoinjectors SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Challenges Associated with Medical Device Manufacturing
Figure 16.2 Services Offered by Medical Device CMOs
Figure 16.3 Advantages of Outsourcing to CMOs
Figure 16.4 Risks Associated with Outsourcing to CMOs
Figure 17.1 Global Autoinjectors Market, 2020-2030 (USD Million)
Figure 17.2 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.3 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.4 Autoinjectors Market in North America, 2020-2030 (USD Million)
Figure 17.5 Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.6 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.7 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.8 Autoinjectors Market in Europe, 2020-2030 (USD Million)
Figure 17.9 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.10 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.11 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.12 Autoinjectors Market in Asia Pacific, 2020-2030 (USD Million)
Figure 17.13 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.14 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.15 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.16 Autoinjectors Market in Rest of the World, 2020-2030 (USD Million)
Figure 17.17 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.18 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.19 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.20 Global Autoinjectors Market, 2020-2030 (Units, Million)
Figure 17.21 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.22 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.23 Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.24 Autoinjectors Market in North America, 2020-2030 (Units, Million)
Figure 17.25 Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.26 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.27 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.28 Autoinjectors Market in Europe, 2020-2030 (Units, Million)
Figure 17.29 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.30 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.31 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.32 Autoinjectors Market in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.33 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.34 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.35 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.36 Autoinjectors Market in Rest of the World, 2020-2030 (Units, Million)
Figure 17.37 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.38 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.39 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.40 Global Autoinjectors Market for Anaphylaxis, 2020-2030 (USD Million)
Figure 17.41 Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (USD Million)
Figure 17.42 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.43 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.44 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.45 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (USD Million)
Figure 17.46 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.47 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.48 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.49 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (USD Million)
Figure 17.50 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.51 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.52 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.53 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (USD Million)
Figure 17.54 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.55 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.56 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.57 Global Autoinjectors Market for Anaphylaxis, 2020-2030 (Units, Million)
Figure 17.58 Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (Units, Million)
Figure 17.59 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.60 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.61 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.62 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (Units, Million)
Figure 17.63 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.64 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.65 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.66 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.67 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.68 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.69 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.70 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (Units, Million)
Figure 17.71 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.72 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.73 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.74 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (USD Million)
Figure 17.75 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (USD Million)
Figure 17.76 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.77 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.78 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.79 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (USD Million)
Figure 17.80 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.81 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.82 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.83 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (USD Million)
Figure 17.84 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.85 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.86 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.87 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (USD Million)
Figure 17.88 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.89 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.90 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.91 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (Units, Million)
Figure 17.92 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (Units, Million)
Figure 17.93 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.94 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.95 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.96 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (Units, Million)
Figure 17.97 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.98 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.99 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.100 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.101 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.102 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.103 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.104 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (Units, Million)
Figure 17.105 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.106 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.107 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.108 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (USD Million)
Figure 17.109 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (USD Million)
Figure 17.110 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.111 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.112 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.113 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (USD Million)
Figure 17.114 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.115 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.116 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.117 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (USD Million)
Figure 17.118 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.119 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.120 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.121 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (USD Million)
Figure 17.122 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.123 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.124 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.125 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (Units, Million)
Figure 17.126 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (Units, Million)
Figure 17.127 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.128 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.129 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.130 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (Units, Million)
Figure 17.131 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.132 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.133 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.134 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.135 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.136 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.137 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.138 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (Units, Million)
Figure 17.139 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.140 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.141 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.142 Global Autoinjectors Market for Migraine, 2020-2030 (USD Million)
Figure 17.143 Autoinjectors Market for Migraine in North America, 2020-2030 (USD Million)
Figure 17.144 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.145 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.146 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.147 Autoinjectors Market for Migraine in Europe, 2020-2030 (USD Million)
Figure 17.148 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.149 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.150 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.151 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (USD Million)
Figure 17.152 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.153 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.154 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.155 Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (USD Million)
Figure 17.156 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.157 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.158 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.159 Global Autoinjectors Market for Migraine, 2020-2030 (Units, Million)
Figure 17.160 Autoinjectors Market for Migraine in North America, 2020-2030 (Units, Million)
Figure 17.161 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.162 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.163 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.164 Autoinjectors Market for Migraine in Europe, 2020-2030 (Units, Million)
Figure 17.165 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.166 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.167 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.168 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.169 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.170 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.171 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.172 Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (Units, Million)
Figure 17.173 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.174 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.175 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.176 Global Autoinjectors Market for Diabetes, 2020-2030 (USD Million)
Figure 17.177 Autoinjectors Market for Diabetes in North America, 2020-2030 (USD Million)
Figure 17.178 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.179 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.180 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.181 Autoinjectors Market for Diabetes in Europe, 2020-2030 (USD Million)
Figure 17.182 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.183 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.184 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.185 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (USD Million)
Figure 17.186 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.187 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.188 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.189 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (USD Million)
Figure 17.190 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.191 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.192 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.193 Global Autoinjectors Market for Diabetes, 2020-2030 (Units, Million)
Figure 17.194 Autoinjectors Market for Diabetes in North America, 2020-2030 (Units, Million)
Figure 17.195 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.196 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.197 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.198 Autoinjectors Market for Diabetes in Europe, 2020-2030 (Units, Million)
Figure 17.199 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.200 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.201 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.202 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.203 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.204 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.205 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.206 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (Units, Million)
Figure 17.207 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.208 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.209 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.210 Global Autoinjectors Market for Other Indications, 2020-2030 (USD Million)
Figure 17.211 Autoinjectors Market for Other Indications in North America, 2020-2030 (USD Million)
Figure 17.212 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.213 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.214 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.215 Autoinjectors Market for Other Indications in Europe, 2020-2030 (USD Million)
Figure 17.216 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.217 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.218 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.219 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (USD Million)
Figure 17.220 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.221 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.222 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.223 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (USD Million)
Figure 17.224 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.225 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.226 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.227 Global Autoinjectors Market for Other Indications, 2020-2030 (Units, Million)
Figure 17.228 Autoinjectors Market for Other Indications in North America, 2020-2030 (Units, Million)
Figure 17.229 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.230 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.231 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.232 Autoinjectors Market for Other Indications in Europe, 2020-2030 (Units, Million)
Figure 17.233 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.234 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.235 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.236 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.237 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.238 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.239 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.240 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (Units, Million)
Figure 17.241 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.242 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.243 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)

List Of  Tables
Table 3.1 Comparison of Self-Injection Devices
Table 3.2 Benefits of Autoinjectors
Table 4.1 Cartridge Manufacturers
Table 4.2 Glass Prefilled Syringes Available in the Market
Table 4.3 Plastic Prefilled Syringes Available in the Market
Table 4.4 Vials Available in the Market
Table 4.5 Comparison of Fabrication Material Used for Primary Drug Containers
Table 5.1 Autoinjectors: List of Devices
Table 5.2 Autoinjectors: List of Developers
Table 8.1 Patent Portfolio: CPC Symbols
Table 8.2 Patent Portfolio: Most Popular CPC Symbols
Table 8.3 Patent Portfolio: List of Top CPC Symbols
Table 8.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
Table 8.5 Patent Portfolio: List of Relatively Higher Value Patents
Table 9.1 Autoinjector Combination Products: List of Approved Drugs
Table 9.2 Autoinjector Combination Products: List of Pipeline Drugs
Table 9.3 Autoinjector Combination Products: List of Developers
Table 10.1 Autoinjector-based Combination Products Available / Under Evaluation
Table 10.2 Adrenaline: Commercially Available Autoinjectors
Table 10.3 Adrenaline: Other Formulations
Table 10.4 Interferon β-1a Autoinjectors
Table 10.5 Interferon β-1b Autoinjectors
Table 10.6 Interferon-β Drugs: Other Dosage Forms
Table 10.7 Migraine: Commercially Available Autoinjectors
Table 10.8 Sumatriptan Succinate: Other Formulations
Table 10.9 Rheumatoid Arthritis: Commercially Available Autoinjectors
Table 11.1 Marketed Molecules: Most Likely Drug Candidates
Table 11.2 Marketed Molecules: Likely Drug Candidates
Table 11.3 Marketed Molecules: Less Likely Drug Candidates
Table 11.4 Marketed Molecules: Unlikely Drug Candidates
Table 11.5 Pipeline Molecules: Most Likely Drug Candidates
Table 11.6 Pipeline Molecules: Likely Drug Candidates
Table 11.7 Pipeline Molecules: Less Likely Drug Candidates
Table 11.8 Pipeline Molecules: Unlikely Drug Candidates
Table 12.1 Antares Pharma: Recent Developments and Future Outlook
Table 12.2 Consort Medical: Recent Developments and Future Outlook
Table 12.3 DALI Medical Devices: Recent Developments and Future Outlook
Table 12.4 Elcam Medical: Comparison of Autoinjectors
Table 12.5 Elcam Medical: Recent Developments and Future Outlook
Table 12.6 Jiangsu Delfu: Autoinjectors
Table 12.7 Delfu Autoinjectors: Specifications
Table 12.8 Oval Medical Technologies: Recent Developments and Future Outlook
Table 12.9 Owen Mumford: Comparison of Autoinjectors
Table 12.10 Owen Mumford: Recent Developments and Future Outlook
Table 12.11 SHL: Comparison of Two-Step Disposable Autoinjectors
Table 12.12 SHL: Comparison of Three-Step Disposable Autoinjectors
Table 12.13 SHL Group: Recent Developments and Future Outlook
Table 12.14 Union Medico: Comparison of 45˚ Autoinjectors
Table 12.15 Union Medico: Comparison of 90˚ Autoinjectors
Table 12.16 Ypsomed: Comparison of Autoinjectors
Table 12.17 Ypsomed: Recent Developments and Future Outlook
Table 13.1 AktiVax: Company Details
Table 13.2 Amneal Pharmaceuticals: Company Details
Table 13.3 kaléo: Company Details
Table 13.4 MiniEpi: Company Details
Table 13.5 Nemera: Company Details
Table 13.6 Nuance Designs: Company Details
Table 13.7 Windgap Medical: Company Details
Table 13.8 Xeris Pharmaceuticals: Company Details
Table 13.9 Zion Clinical Pharmacy: Company Details
Table 14.1 KOL Analysis: List of Principal Investigators / Sub-Investigators / Study Directors
Table 14.2 KOL Analysis: Number of Publications and Citations
Table 14.3 KOL Analysis: List of Patents Applicants
Table 14.4 KOL Analysis: Number of Affiliations, LinkedIn Connections and Years of Experience
Table 16.1 List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 16.2 Medical Device CMOs Offering Services for Drug Delivery Devices: Information on Production Services
Table 18.1 Conclusion: Key Takeaways
Table 19.1 PHC: Company Snapshot
Table 19.2 Elcam Medical: Company Snapshot
Table 19.3 DALI Medical Devices: Company Snapshot
Table 20.1 Autoinjectors: Distribution by Usability
Table 20.2 Autoinjectors: Distribution by Type of Primary Container
Table 20.3 Autoinjectors: Distribution by Volume of Container
Table 20.4 Autoinjectors: Distribution by Type of Dose
Table 20.5 Autoinjectors: Distribution by Route of Administration
Table 20.6 Autoinjectors: Distribution by Actuation Mechanism
Table 20.7 Autoinjectors: Distribution by Type of Feedback System
Table 20.8 Autoinjector Device Developers: Distribution by Year of Establishment
Table 20.9 Autoinjector Device Developers: Distribution by Company Size
Table 20.10 Autoinjector Device Developers: Distribution by Geographical Location of Headquarters
Table 20.11 Autoinjector Device Developers: Distribution by Geographical Location of Manufacturing Facilities
Table 20.12 Patent Portfolio: Distribution by Type of Patent
Table 20.13 Patent Portfolio: Cumulative Distribution by Application Year
Table 20.14 Patent Portfolio: Year-wise Distribution by Application Year
Table 20.15 Patent Portfolio: Distribution by Issuing Authority
Table 20.16 Patent Portfolio: Distribution by CPC Symbols
Table 20.17 Leading Players: Distribution by Number of Patents
Table 20.18 Patent Portfolio: Distribution of Patents by Geography and Type
Table 20.19 Patent Portfolio: Age of Patents
Table 20.20 Patent Portfolio: Valuation Analysis
Table 20.21 Approved Autoinjector Combination Products: Distribution by Initial year of Approval
Table 20.22 Approved Autoinjector Combination Products: Distribution by Usability of Product
Table 20.23 Approved Autoinjector Combination Products: Distribution by Route of Administration
Table 20.24 Approved Autoinjector Combination Products: Distribution by Type of Molecule
Table 20.25 Approved Autoinjector Combination Products: Distribution by Dose Strength
Table 20.26 Approved Autoinjector Combination Products: Distribution by Therapeutic Area
Table 20.27 Approved Autoinjector Combination Products: Distribution by Other Approved Dosage Forms
Table 20.28 Pipeline Autoinjector Combination Products: Distribution by Phase of Development
Table 20.29 Pipeline Autoinjector Combination Products: Distribution by Route of Administration
Table 20.30 Pipeline Autoinjector Combination Products: Distribution by Type of Molecule
Table 20.31 Pipeline Autoinjector Combination Products: Distribution by Therapeutic Area
Table 20.32 Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 20.33 Autoinjector Combination Product Developers: Distribution by Company Size
Table 20.34 Autoinjector Combination Product Developers: Distribution by Geographical Location of Headquarters
Table 20.35 EpiPen: Historical Drug Sales (USD Billion), 2012-2017
Table 20.36 Interferon β-1a: Historical Sales (USD Billion), 2014-H1 2019
Table 20.37 Interferon β-1b: Historical Sales (USD Million), 2014-H1 2019
Table 20.38 Migraine: Historical Drug Sales (USD Million), 2014-H1 2019
Table 20.39 Rheumatoid Arthritis: Historical Drug Sales (USD Billion), 2014-H1 2019
Table 20.40 Antares Pharma: Annual Revenues, 2014-H1 2019 (USD Million)
Table 20.41 Consort Medical: Annual Revenues, FY 13/14-FY 18/19 (GBP Million)
Table 20.42 Ypsomed: Annual Revenues, FY 14/15-FY 18/19 (CHF Million)
Table 20.43 Ypsomed: Sales by Business Divisions, FY 18/19 (CHF Million, %)
Table 20.44 Global Autoinjectors Market, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.45 Global Autoinjectors Market: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.46 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.47 Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.48 Autoinjectors Market in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.49 Autoinjectors Market in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.50 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.51 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.52 Autoinjectors Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.53 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.54 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.55 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.56 Autoinjectors Market in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.57 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.58 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.59 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.60 Autoinjectors Market in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.61 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.62 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.63 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.64 Global Autoinjectors Market, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.65 Global Autoinjectors Market: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.66 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.67 Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.68 Autoinjectors Market in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.69 Autoinjectors Market in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.70 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.71 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.72 Autoinjectors Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.73 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.74 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.75 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.76 Autoinjectors Market in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.77 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.78 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.79 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.80 Autoinjectors Market in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.81 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.82 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.83 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.84 Global Autoinjectors Market for Anaphylaxis, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.85 Autoinjectors Market for Anaphylaxis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.86 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.87 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.88 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.89 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.90 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.91 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.92 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.93 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.94 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.95 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.96 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.97 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.98 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.99 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.100 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.101 Global Autoinjectors Market for Anaphylaxis, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.102 Autoinjectors Market for Anaphylaxis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.103 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.104 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.105 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.106 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.107 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.108 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.109 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.110 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.111 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.112 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.113 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.114 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.115 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.116 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.117 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.118 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.119 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.120 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.121 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.122 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.123 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.124 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.125 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.126 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.127 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.128 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.129 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.130 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.131 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.132 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.133 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.134 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.135 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.136 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.137 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.138 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.139 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.140 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.141 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.142 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.143 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.144 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.145 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.146 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.147 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.148 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.149 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.150 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.151 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.152 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.153 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.154 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.155 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.156 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.157 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.158 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.159 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.160 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.161 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.162 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.163 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.164 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.165 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.166 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.167 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.168 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.169 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.170 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.171 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.172 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.173 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.174 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.175 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.176 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.177 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.178 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.179 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.180 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.181 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.182 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.183 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.184 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.185 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.186 Global Autoinjectors Market for Migraine, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.187 Autoinjectors Market for Migraine in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.188 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.189 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.190 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.191 Autoinjectors Market for Migraine in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.192 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.193 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.194 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.195 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.196 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.197 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.198 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.199 Autoinjectors Market for Migraine in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.200 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.201 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.202 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.203 Global Autoinjectors Market for Migraine, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.204 Autoinjectors Market for Migraine in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.205 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.206 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.207 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.208 Autoinjectors Market for Migraine in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.209 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.210 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.211 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.212 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.213 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.214 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.215 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.216 Autoinjectors Market for Migraine in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.217 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.218 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.219 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.220 Global Autoinjectors Market for Diabetes, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.221 Autoinjectors Market for Diabetes in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.222 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.223 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.224 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.225 Autoinjectors Market for Diabetes in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.226 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.227 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.228 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.229 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.230 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.231 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.232 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.233 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.234 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.235 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.236 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.237 Global Autoinjectors Market for Diabetes, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.238 Autoinjectors Market for Diabetes in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.239 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.240 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.241 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.242 Autoinjectors Market for Diabetes in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.243 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.244 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.245 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.246 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.247 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.248 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.249 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.250 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.251 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.252 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.253 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.254 Global Autoinjectors Market for Other Indications, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.255 Autoinjectors Market for Other Indications in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.256 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.257 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.258 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.259 Autoinjectors Market for Other Indications in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.260 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.261 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.262 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.263 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.264 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.265 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.266 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.267 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.268 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.269 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.270 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.271 Global Autoinjectors Market for Other Indications, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.272 Autoinjectors Market for Other Indications in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.273 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.274 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.275 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.276 Autoinjectors Market for Other Indications in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.277 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.278 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.279 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.280 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.281 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.282 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.283 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.284 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.285 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.286 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.287 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • AktiVax
  • ALK-Abelló
  • Allergy Therapeutics
  • Alvogen
  • Alvotech
  • AMAG Pharmaceuticals
  • AMETEK Engineered Medical Components
  • Amgen
  • Amneal Pharmaceuticals
  • Amsino
  • Androsystems
  • Antares Pharma
  • Apex Medical Technologies
  • Asahi Kasei Pharma
  • Ascendis Pharma
  • AstraZeneca
  • Atrion
  • B&A Health
  • Bausch Health Companies
  • Bayer
  • BD
  • Bespak
  • BIOCORP LIFE SCIENCES
  • Biogen
  • BioGene Pharmaceutical
  • Biomerics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • Canon Virginia
  • Carclo
  • Celltrion
  • ChemProtect
  • Chugai Pharmaceutical
  • CinnaGen
  • Cirtec Medical
  • Consort Medical
  • Contract Medical International
  • Creare
  • Crossject
  • Doctor Pack
  • Donatelle
  • Dr. Reddy's Laboratory
  • DSM
  • Duoject Medical Systems
  • EA Pharma
  • Eastek International
  • EG-GILERO
  • Eisai
  • Elcam Drug Delivery Devices
  • Eli Lilly
  • EMD Serono
  • Europlaz Technologies
  • Evergreen Research
  • Fabrico Medical
  • Ferring Pharmaceuticals
  • Flex
  • Forefront Medical Technology
  • Fresenius Kabi
  • Freudenberg Medical
  • Fujifilm Kyowa Kirin Biologics
  • Genentech
  • Gerresheimer
  • GlaxoSmithKline
  • GW Plastics
  • H&T Presspart
  • Haselmeier
  • Haywood Vocational Opportunities
  • Hoffmann-La Roche
  • IEC Electronics
  • Immunex
  • Integer
  • Interplex
  • Inzign
  • Jabil
  • Janssen Biotech
  • JCR Pharmaceuticals
  • Jiangsu Delfu medical device
  • Kaléo
  • King Pharmaceuticals
  • Lincoln Medical Centre
  • Lineage Therapeutics
  • Lupin
  • M&M Qualtech
  • Mack Molding
  • Medac Pharma
  • Medeca Pharma
  • Medicom Innovation Partner
  • Merck
  • Meridian Medical Technologies
  • Midwest Interventional Systems
  • MiniEpi
  • Modulus
  • Momenta Pharmaceuticals
  • Mylan
  • NACS
  • Natech Plastics
  • Nemera
  • NeoTech Medical
  • Nexeon MedSystems
  • Novartis
  • Nuance Designs
  • Occam Design
  • Ology Bioservices
  • Oval Medical Technologies
  • Owen Mumford
  • P3 Medical
  • PA Consulting Group
  • Palatin Technologies
  • Paramit
  • Peridot
  • Pfizer
  • Pharma Tech
  • PHC Injection Device Technologies
  • Phillips-Medisize
  • Plastikon
  • Plexus
  • Polyzen
  • Precision Engineered Products
  • Precision MicroFab
  • Preco
  • Pro-Dex
  • Promius Pharma
  • Proven Process Medical Devices
  • Providence Enterprise
  • Quality Tech Services
  • Rafa Laboratories
  • RaviMed
  • Regeneron Pharmaceuticals
  • Riverside Medical Packaging
  • Roche
  • Röchling Medical
  • Samsung Bioepis
  • SanaVita Medical
  • Sandoz
  • Sanmina
  • Sanofi
  • Shire
  • SHL Group
  • SMC
  • Sovrin Plastics
  • Stellartech Research
  • SteriPack
  • Stevanato Group
  • Sumitomo Dainippon Pharma
  • Sun Pharmaceutical
  • Survival Technologies
  • Switchback Medical
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Trelleborg Sealing Solutions
  • Trend Technologies
  • TRICOR Systems
  • UCB Biopharma
  • Uman Pharma
  • Union Medico
  • US WorldMeds
  • Valtronic
  • VascuTech Medical
  • Vaupell
  • ViVO Smart Medical Devices
  • West Pharmaceutical Services
  • Westmed
  • Windgap Medical
  • Xeris Pharmaceuticals
  • YL Biologics
  • Ypsomed
  • Zenius
  • Zion Clinic Pharmacy
Note: Product cover images may vary from those shown
5 of 4

 

 

Loading
LOADING...

Adroll
adroll